ACLARIS THERAPEUTICS INC (ACRS) Stock News

Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)...

Aclaris Stock Rises As Analyst Projects Billions In Sales For New Therapy

HC Wainwright upgraded Aclaris Therapeutics (ACRS) to Buy with a $20 price target. Aclaris gains after licensing agreement with Biosion for potential best-in-class therapies for atopic dermatitis and asthma.

This Weyerhaeuser Analyst Turns Bullish; Here Are Top 4 Upgrades For Monday

Pony AI, Thermo Fisher initiated: Wall Street's top analyst calls

Pony AI, Thermo Fisher initiated: Wall Street's top analyst calls

Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)...

Aclaris Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference

Aclaris Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference ...

Biosion Announces Exclusive, Global License Agreement with Aclaris Therapeutics on two potential First-in-Class and Best-in-Class Immunology Assets

Biosion receives over $40 million cash payment as upfront license fee and reimbursement for certain development costs & drug product materials, and 19.9%...

Aclaris Therapeutics Announces Exclusive, Global License Agreement with Biosion, Inc., adding Potential Best-in-Class Biologics Assets to Pipeline

Aclaris Therapeutics Announces Exclusive, Global License Agreement with Biosion, Inc., adding Potential Best-in-Class Biologics Assets to Pipeline...

Aclaris Therapeutics Announces $80 Million Private Placement

Aclaris Therapeutics Announces $80 Million Private Placement...

Aclaris Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update

Aclaris Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update ...

Aclaris Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor for the Treatment of Moderate to Severe Atopic Dermatitis

Aclaris Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor for the...

Aclaris Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference

Aclaris Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference...

Aclaris Therapeutics Reports Second Quarter 2024 Financial Results and Provides a Corporate Update

Aclaris Therapeutics Reports Second Quarter 2024 Financial Results and Provides a Corporate Update...

Aclaris Therapeutics Announces Sale of OLUMIANT® Royalties and Milestones to OMERS Life Sciences for Up to $31.5 Million

Aclaris Therapeutics Announces Sale of OLUMIANT® Royalties and Milestones to OMERS Life Sciences for Up to $31.5 Million...

3 Beaten Down Pharmaceuticals With Catalysts for Higher Prices

Beaten-down stocks offer value to investors, but not all are worth buying. This is a look at three biopharma at long-term lows with catalysts for higher prices.

Aclaris Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

Aclaris Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference...

ACRS Stock Earnings: Aclaris Therapeutics Beats EPS, Beats Revenue for Q1 2024

ACRS stock results show that Aclaris Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.

ACRS Stock Earnings: Aclaris Therapeutics Beats EPS, Beats Revenue for Q1 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Aclaris Therapeutics (NASDAQ:ACRS) just reported results for the first quarter ...

Aclaris Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update

Aclaris Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update...

Biotech’s Role in Addressing the Pancreatic Cancer Emergency

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:NVX),(NASDAQ:IBRX),(NASDAQ:ACRS),(NYSE:NUVB) EQNX::TICKER_END

Biotech's Role in Addressing the Pancreatic Cancer Emergency

/PRNewswire/ -- USA News Group - Known as one of the most deadly forms of cancer, pancreatic cancer still has the highest mortality rate of all major cancers...

Aclaris Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update

WAYNE, Pa., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing...